Full-Time

Associate IS Bus Sys Analyst

Posted on 7/6/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Entry, Junior, Mid

Hyderabad, Telangana, India

In Person

Category
Backend Engineering
IT & Support
Software Engineering
Required Skills
NoSQL
SQL
Requirements
  • Solid technical background, including understanding software development processes, databases, and cloud-based systems.
  • Experience configuring SaaS applications (such as Veeva).
  • Experience working with databases (SQL/NoSQL).
  • Strong foundational knowledge of testing methodologies.
Responsibilities
  • Maintain existing code and configuration: Support and maintain SaaS applications
  • Development & Deployment: Develop, test, and deploy code based on designs created with the guidance of senior team members. Implement solutions following standard methodologies for code structure and efficiency.
  • Documentation: Generate clear and concise code documentation for new and existing features to ensure smooth handovers and easy future reference.
  • Collaborative Design: Work closely with team members and collaborators to understand project requirements and translate them into functional technical designs.
  • Code Reviews & Quality Assurance: Participate in peer code reviews, providing feedback on consistency to standard methodologies, and ensuring high code quality and maintainability.
  • Testing & Debugging: Assist in writing unit and integration tests to validate new features and functionalities. Support fix and debugging efforts for existing systems to resolve bugs and performance issues.
  • Perform application support and administration tasks such as periodic review, manage incident response and resolution, and security reviews.
  • Continuous Learning: Stay up-to-date with the newest technologies and standard methodologies, with a focus on expanding knowledge in cloud services, automation, and secure software development.
Desired Qualifications
  • Understanding of Veeva Quality Vault/ALM/KNEAT.
  • Curiosity of modern technology domain and learning agility
  • Experience with the following technologies: Veeva Vault, MuleSoft, AWS (Amazon Web Services) Services (DynamoDB, EC2, S3, etc.), Application Programming Interface (API) integration and Structured Query Language (SQL) will be a big plus.
  • Superb communication skills, with the ability to convey complex technical concepts.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The company's goal is to improve patient care and outcomes by providing effective therapeutic solutions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.